Last reviewed · How we verify
Janssen-Cilag Ltd. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Risperidone prolonged release | Risperidone prolonged release | marketed | ||||
| TMC114/ritonavir | TMC114/ritonavir | marketed | HIV protease inhibitor | HIV protease | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Baqiyatallah Medical Sciences University · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- Community Research Initiative of New England · 1 shared drug class
- Drugs for Neglected Diseases · 1 shared drug class
- DualityBio Inc. · 1 shared drug class
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
- Far East Bio-Tec Co., Ltd · 1 shared drug class
- Abbott · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Janssen-Cilag Ltd.:
- Janssen-Cilag Ltd. pipeline updates — RSS
- Janssen-Cilag Ltd. pipeline updates — Atom
- Janssen-Cilag Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Janssen-Cilag Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-cilag-ltd. Accessed 2026-06-10.